Does the media prefer ORIC or TRDA?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat Oric Pharmaceuticals' score of 1.19 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OLMA or TRDA?

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 3 articles in the media. Entrada Therapeutics' average media sentiment score of 1.19 beat Olema Pharmaceuticals' score of 1.07 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SANA or TRDA?

In the previous week, Sana Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat Sana Biotechnology's score of 0.57 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOA or TRDA?

In the previous week, BioAge Labs had 2 more articles in the media than Entrada Therapeutics. MarketBeat recorded 5 mentions for BioAge Labs and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat BioAge Labs' score of 0.20 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRDA or XNCR?

In the previous week, Xencor had 2 more articles in the media than Entrada Therapeutics. MarketBeat recorded 5 mentions for Xencor and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat Xencor's score of 1.00 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Entrada Therapeutics (TRDA) Competitors

$7.11 +0.31 (+4.56%)

Closing price 04:00 PM Eastern

Extended Trading

$7.10 0.00 (-0.07%)

As of 06:34 PM Eastern

Compare

TRDA vs. ORIC, OLMA, SANA, BIOA, and XNCR

Should you buy Entrada Therapeutics stock or one of its competitors? MarketBeat compares Entrada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entrada Therapeutics include Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA), Sana Biotechnology (SANA), BioAge Labs (BIOA), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Entrada Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Oric Pharmaceuticals has higher earnings, but lower revenue than Entrada Therapeutics. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Entrada Therapeutics	$25.42M	10.86	-$143.75M	-$3.99	N/A

Oric Pharmaceuticals has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Oric Pharmaceuticals presently has a consensus price target of $19.27, suggesting a potential upside of 73.00%. Entrada Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 146.13%. Given Entrada Therapeutics' higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Oric Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Oric Pharmaceuticals' return on equity of -35.33% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat Oric Pharmaceuticals' score of 1.19 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oric Pharmaceuticals beats Entrada Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Olema Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Olema Pharmaceuticals' return on equity of -46.00% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Olema Pharmaceuticals has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Entrada Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Entrada Therapeutics	$25.42M	10.86	-$143.75M	-$3.99	N/A

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 3 articles in the media. Entrada Therapeutics' average media sentiment score of 1.19 beat Olema Pharmaceuticals' score of 1.07 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals currently has a consensus target price of $44.10, indicating a potential upside of 273.10%. Entrada Therapeutics has a consensus target price of $17.50, indicating a potential upside of 146.13%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Olema Pharmaceuticals is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Olema Pharmaceuticals beats Entrada Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Entrada Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

In the previous week, Sana Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat Sana Biotechnology's score of 0.57 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Entrada Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Entrada Therapeutics	$25.42M	10.86	-$143.75M	-$3.99	N/A

Sana Biotechnology has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

Sana Biotechnology presently has a consensus target price of $9.50, indicating a potential upside of 167.61%. Entrada Therapeutics has a consensus target price of $17.50, indicating a potential upside of 146.13%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Sana Biotechnology beats Entrada Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

BioAge Labs has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

In the previous week, BioAge Labs had 2 more articles in the media than Entrada Therapeutics. MarketBeat recorded 5 mentions for BioAge Labs and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat BioAge Labs' score of 0.20 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.4% of Entrada Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioAge Labs presently has a consensus price target of $43.50, suggesting a potential upside of 91.63%. Entrada Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 146.13%. Given Entrada Therapeutics' higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

BioAge Labs has higher earnings, but lower revenue than Entrada Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	97.82	-$80.61M	-$2.40	N/A
Entrada Therapeutics	$25.42M	10.86	-$143.75M	-$3.99	N/A

BioAge Labs has a net margin of -871.75% compared to Entrada Therapeutics' net margin of -2,895.05%. BioAge Labs' return on equity of -29.40% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Summary

BioAge Labs beats Entrada Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Xencor?

Entrada Therapeutics (NASDAQ:TRDA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Xencor had 2 more articles in the media than Entrada Therapeutics. MarketBeat recorded 5 mentions for Xencor and 3 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.19 beat Xencor's score of 1.00 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 146.13%. Xencor has a consensus price target of $24.25, suggesting a potential upside of 61.88%. Given Entrada Therapeutics' higher possible upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Xencor has a net margin of -177.10% compared to Entrada Therapeutics' net margin of -2,895.05%. Xencor's return on equity of -28.77% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Xencor	-177.10%	-28.77%	-20.52%

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Xencor has higher revenue and earnings than Entrada Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.86	-$143.75M	-$3.99	N/A
Xencor	$97.36M	11.41	-$91.92M	-$2.29	N/A

Summary

Xencor beats Entrada Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$276.01M	$3.67B	$6.77B	$12.66B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-1.78	21.50	27.12	24.38
Price / Sales	10.86	327.23	527.54	93.36
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	0.89	8.57	10.82	6.32
Net Income	-$143.75M	$23.88M	$3.59B	$331.55M
7 Day Performance	-2.87%	-2.32%	-1.21%	0.08%
1 Month Performance	8.22%	6.47%	3.13%	-0.76%
1 Year Performance	11.62%	53.33%	29.12%	20.68%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	3.1533 of 5 stars	$7.11 +4.6%	$17.50 +146.1%	+0.0%	$276.01M	$25.42M	N/A	110	Positive News
ORIC Oric Pharmaceuticals	2.3481 of 5 stars	$10.88 -0.3%	$19.27 +77.1%	-2.8%	$1.13B	N/A	N/A	80	News Coverage
OLMA Olema Pharmaceuticals	2.3278 of 5 stars	$12.63 -1.1%	$44.10 +249.2%	+145.3%	$1.12B	N/A	N/A	70	News Coverage Positive News Analyst Upgrade
SANA Sana Biotechnology	2.9867 of 5 stars	$4.12 +3.8%	$9.50 +130.6%	-15.4%	$1.10B	N/A	N/A	380	News Coverage Analyst Upgrade
BIOA BioAge Labs	2.404 of 5 stars	$24.40 -1.8%	$43.50 +78.3%	+392.0%	$1.10B	$8.99M	N/A	N/A	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ORIC, OLMA, SANA, BIOA, and XNCR

How does Entrada Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Entrada Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Summary

How does Entrada Therapeutics compare to BioAge Labs?

Summary

How does Entrada Therapeutics compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ORIC, OLMA, SANA, BIOA, and XNCR

How does Entrada Therapeutics compare to Oric Pharmaceuticals?

Which has higher valuation and earnings, ORIC or TRDA?

Which has more volatility and risk, ORIC or TRDA?

Do analysts recommend ORIC or TRDA?

Is ORIC or TRDA more profitable?

Do insiders and institutionals hold more shares of ORIC or TRDA?

Does the media prefer ORIC or TRDA?

Summary

How does Entrada Therapeutics compare to Olema Pharmaceuticals?

Is OLMA or TRDA more profitable?

Do institutionals and insiders believe in OLMA or TRDA?

Which has more volatility and risk, OLMA or TRDA?

Which has better earnings and valuation, OLMA or TRDA?

Does the media favor OLMA or TRDA?

Do analysts rate OLMA or TRDA?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Does the media favor SANA or TRDA?

Is SANA or TRDA more profitable?

Do insiders & institutionals have more ownership in SANA or TRDA?

Which has higher valuation and earnings, SANA or TRDA?

Which has more risk & volatility, SANA or TRDA?

Do analysts rate SANA or TRDA?

Summary

How does Entrada Therapeutics compare to BioAge Labs?

Which has more risk and volatility, BIOA or TRDA?

Does the media prefer BIOA or TRDA?

Do insiders & institutionals hold more shares of BIOA or TRDA?

Do analysts recommend BIOA or TRDA?

Which has preferable earnings and valuation, BIOA or TRDA?

Is BIOA or TRDA more profitable?

Summary

How does Entrada Therapeutics compare to Xencor?

Does the media favor TRDA or XNCR?

Do analysts prefer TRDA or XNCR?

Which has more volatility & risk, TRDA or XNCR?

Is TRDA or XNCR more profitable?

Do insiders & institutionals hold more shares of TRDA or XNCR?

Which has better valuation & earnings, TRDA or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools